CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Operating activities
Net loss	$ (121,291)	$ (69,609)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,348	3,926
Equity-based compensation	12,539	11,162
Change in fair value of warrants	(2,006)	19,523
Debt extinguishment loss	13,734
Issuance of common warrants	9,006
Change in fair value of derivative liability	36,407
Change in fair value of asset purchase agreement liability		(2,217)
Realized and unrealized gain on short term investments	(2,204)	(517)
Equity method investment loss	119	118
Asset retirement obligation accretion	78	51
Amortization of debt discount	6,878	4,526
Changes in operating assets and liabilities:
Accounts receivable	1,869	97
Other current assets	(511)	269
Other assets	121	60
Accounts payable	(21)	527
Deferred revenue	134	6
Accrued expenses and other liabilities	3,483	5,144
Operating lease right-of-use assets and liabilities	649	874
Net cash used in operating activities	(34,668)	(26,060)
Investing activities
Purchases of network assets, property, and equipment	(65)	(182)
Purchase of internal use software	(310)	(354)
Purchase of marketable securities	(194,494)	(44,894)
Sale and maturity of marketable securities	159,900	30,500
Payment for asset purchase agreement liability		(2,732)
Net cash used in investing activities	(34,969)	(17,662)
Financing activities
Proceeds from 2028 senior convertible notes	190,000
Repayment of 2026 senior secured notes	(70,700)
Payments towards debt issuance cost	(1,517)
Payments towards debt	(86)	(82)
Proceeds from exercise of common warrants	766	27,896
Redemption of non-controlling interests		40
Proceeds from exercise of common stock options	1,614	1,882
Net cash provided by financing activities	120,077	29,736
Effect of exchange rates on cash and cash equivalents	224	13
Net increase (decrease) in cash and cash equivalents	50,664	(13,973)
Cash and cash equivalents at beginning of period	39,330	81,878
Cash and cash equivalents at end of period	89,994	67,905
Non-cash investing and financing information and supplemental disclosures
Capital expenditure included in Accrued expenses and other current liabilities	23	159
Interest paid in shares of common stock		1,867
Interest paid in cash	4,244	1,750
Issuance of shares for asset purchase agreement	$ 20,394